BioSig Technologies, Inc. STEX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$506.66M-5,102% | -$462.78M-4,380% | -$39.87M-161% | -$26.2M-46.1% | -$9.74M+61.2% | ||
| -$98.85M-705% | -$67.56M-433% | -$28.55M-62.3% | -$26.85M-44.1% | -$12.28M+49.3% | ||
| -$103.86M-737% | -$71.1M-453% | -$30.65M-71.7% | -$27.48M-45.0% | -$12.41M+49.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioSig Technologies, Inc.'s revenue?
- BioSig Technologies, Inc. (STEX) generated $40.0K in revenue over the trailing twelve months, up 122.2% year over year.
- Is BioSig Technologies, Inc. profitable?
- BioSig Technologies, Inc. is not currently profitable: it reported a net loss of $506.7M over the trailing twelve months, a -25825.0% net margin.
- What are BioSig Technologies, Inc.'s profit margins?
- Gross margin is 80.1% and operating margin is -32155.0%, with a -25825.0% net margin.
- What is BioSig Technologies, Inc.'s earnings per share?
- BioSig Technologies, Inc.'s diluted EPS over the trailing twelve months is $-9.71.
- Where does BioSig Technologies, Inc.'s income statement data come from?
- Every line is extracted from BioSig Technologies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
